A serious complication of reserpine therapy is the development of a severe depressive state which may carry the risk of suicide and may need electroconvulsive therapy.
Tetrabenazine is a new synthetic drug with an action similar to reserpine. There is some evidence that it may be of value in treating chronic schizophrenia. Table i lists the most commonly used phenothiazine derivatives. They are mainly in three groups: (i) the dimethylamine series, (2) the piperidine series and (3) the piperazine series. 
Phenothiazine Derivatives

Anti-depression Drugs
There are three main groups of drugs used for elevation of mood:
(i) Central nervous system stimulants, amphetamines, pipradol and methyl phenidate.
(2) Monoamine oxidase inhibitors.
(3) Imipramine and chemically allied drugs.
Central Nervous Stimulants
The really important advance in the pharmacotherapy of depression occurred with the discovery of iproniazid and imipramine some 4 to 5 years ago.
Prior to this the only agents available were the stimulants which had very limited application and serious disadvantages.
The main indication for the amphetamine drugs is in patients with short-lasting, early morning depression of moderate or mild degrees of severity.
The disadvantage of amphetamines include tolerance, dependency and addiction. Shortlasting elevation of mood is followed by post medication increased fatigue, irritability and depression.
Monoamine oxidase Inhibitors
The finding that reserpine which sometimes causes depression produces a fall in level of noradrenaline and serotonin in the central nervous system and that iproniazid raises their level with concurrent increased psychomotor activity, provided a stimulating hypothesis for research workers on biochemical and pharmacotherapeutic aspects of depression.
The work of Kline revealed the value of iproniazid in treating depressive illnesses. Iproniazid has a serious disadvantage in causing toxic liver necrosis in some patients which not infrequently proved fatal.
A large series of new monoamine oxidase inhibitors have subsequently been discovered and used for treating depression.
Some of these have already been withdrawn because of toxic effects. The three which have stood the test of time are phenelzine, nialamide, isocarboxazid and tranylcypromine.
None of these drugs is as effective as ECT for severe endogenous depression. They are mainly of value for depressive illnesses of mild or moderate severity. Data on these drugs are given in Its main use is relief of anxiety, tension and overactivity in neuroses.
Captodiamine has anti-histaminic, anti-emetic and some sedative effects. Clinical trials have failed to establish its therapeutic value as a tranquillizer.
Tranquilosedatives differ from the tranquillizing drugs in having no significant action on the autonomic nervous system. They are central nervous system depressants acting on polysynaptic spinal pathways. Extrapyramidal symptoms do not occur and in contrast to major tranquillizers they increase the threshold to convulsions.
Meprobamate was developed from myanesin, a muscle relaxant. Its main use is the treatment of neuroses for relief of anxiety and tension, particularly when associated with increased muscular tension.
When given in high doses over a long period tolerance and withdrawal symptoms may occur and therefore the risk of addiction.
Methaminodiazepoxide ( 
Conclusions
The discovery of new drugs in the past decade has revolutionized psychiatric treatment. Further advances can be expected. The need for careful testing and screening and fully controlled clinical trials before new drugs are marketed is at last becoming recognized and, when fully implemented, will accelerate progress in this important field of treatment for the most distressing illnesses which afflict mankind.
